X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (51452) 51452
Newspaper Article (316) 316
Newsletter (126) 126
Book Chapter (107) 107
Book / eBook (68) 68
Magazine Article (61) 61
Dissertation (16) 16
Publication (9) 9
Conference Proceeding (6) 6
Web Resource (4) 4
Transcript (2) 2
Book Review (1) 1
Paper (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (43860) 43860
male (23511) 23511
female (21874) 21874
middle aged (16910) 16910
liver neoplasms - drug therapy (16757) 16757
oncology (15451) 15451
animals (14074) 14074
aged (13583) 13583
cancer (13091) 13091
adult (11204) 11204
liver cancer (10563) 10563
liver neoplasms - pathology (10427) 10427
liver neoplasms - secondary (9976) 9976
liver (9363) 9363
hepatocellular carcinoma (9280) 9280
carcinoma, hepatocellular - drug therapy (8442) 8442
mice (8127) 8127
carcinoma, hepatocellular - pathology (7846) 7846
treatment outcome (7071) 7071
cell line, tumor (7067) 7067
chemotherapy (7016) 7016
metastasis (6568) 6568
gastroenterology & hepatology (6130) 6130
tumors (6000) 6000
prognosis (5535) 5535
apoptosis (5475) 5475
surgery (5445) 5445
liver neoplasms - metabolism (5220) 5220
care and treatment (5176) 5176
antineoplastic combined chemotherapy protocols - therapeutic use (5162) 5162
hepatoma (5096) 5096
liver neoplasms - therapy (5012) 5012
antineoplastic agents - therapeutic use (4915) 4915
expression (4666) 4666
liver neoplasms - surgery (4514) 4514
therapy (4156) 4156
carcinoma, hepatocellular - metabolism (4141) 4141
analysis (4109) 4109
retrospective studies (4012) 4012
research (3999) 3999
survival (3993) 3993
aged, 80 and over (3949) 3949
health aspects (3938) 3938
hepatocellular-carcinoma (3850) 3850
liver neoplasms - genetics (3810) 3810
medicine & public health (3729) 3729
pharmacology & pharmacy (3586) 3586
liver neoplasms - mortality (3502) 3502
risk factors (3458) 3458
colorectal neoplasms - pathology (3412) 3412
carcinoma, hepatocellular - therapy (3319) 3319
antineoplastic agents - pharmacology (3198) 3198
survival rate (3162) 3162
apoptosis - drug effects (3129) 3129
proteins (3110) 3110
rats (3106) 3106
carcinoma, hepatocellular - genetics (3088) 3088
colorectal cancer (3083) 3083
cancer therapies (2997) 2997
combined modality therapy (2963) 2963
gene expression (2930) 2930
time factors (2855) 2855
cell proliferation - drug effects (2820) 2820
antineoplastic agents - administration & dosage (2813) 2813
patients (2761) 2761
fluorouracil - administration & dosage (2732) 2732
mice, nude (2700) 2700
neoplasm staging (2699) 2699
medicine (2602) 2602
carcinoma (2547) 2547
follow-up studies (2538) 2538
liver - pathology (2487) 2487
medical prognosis (2465) 2465
hep g2 cells (2453) 2453
radiology, nuclear medicine & medical imaging (2440) 2440
research article (2429) 2429
digestive system diseases (2368) 2368
development and progression (2321) 2321
metastases (2297) 2297
cells (2261) 2261
survival analysis (2261) 2261
growth (2251) 2251
mice, inbred balb c (2232) 2232
drug therapy (2193) 2193
carcinoma, hepatocellular - mortality (2185) 2185
dose-response relationship, drug (2170) 2170
infusions, intra-arterial (2142) 2142
tomography, x-ray computed (2135) 2135
biochemistry & molecular biology (2132) 2132
cell biology (2125) 2125
hepatitis (2099) 2099
hepatectomy (2069) 2069
liver - drug effects (2068) 2068
colorectal neoplasms - drug therapy (2051) 2051
kinases (2049) 2049
liver diseases (2047) 2047
liver neoplasms - diagnosis (2045) 2045
liver neoplasms - diagnostic imaging (2025) 2025
disease progression (2024) 2024
liver metastases (2020) 2020
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (13) 13
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Online Resources - Online (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Credit Valley Hospital - Reference (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (48198) 48198
Japanese (2769) 2769
Chinese (667) 667
German (576) 576
French (550) 550
Russian (320) 320
Spanish (166) 166
Italian (163) 163
Hungarian (61) 61
Polish (46) 46
Korean (36) 36
Czech (23) 23
Danish (22) 22
Dutch (19) 19
Ukrainian (15) 15
Portuguese (11) 11
Swedish (11) 11
Romanian (9) 9
Bulgarian (8) 8
Finnish (6) 6
Hebrew (6) 6
Croatian (5) 5
Norwegian (4) 4
Serbian (4) 4
Arabic (3) 3
Lithuanian (2) 2
Slovak (2) 2
Icelandic (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
American Journal of Pathology, ISSN 0002-9440, 2010, Volume 177, Issue 4, pp. 1647 - 1656
Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream... 
ADJUVANT CHEMOTHERAPY | INHIBITION | THERAPY | PROTEIN | HUMAN-BREAST-CANCER | PATHWAY | MUTATIONS | PATHOLOGY | RECEPTORS | TRASTUZUMAB RESISTANCE | EXPRESSION | Lung Neoplasms - drug therapy | Receptors, Estrogen - metabolism | Receptor, ErbB-2 - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Immunoenzyme Techniques | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Ductal, Breast - drug therapy | Brain Neoplasms - mortality | Liver Neoplasms - secondary | Proto-Oncogene Proteins c-akt - metabolism | Carcinoma, Ductal, Breast - metabolism | PTEN Phosphohydrolase - genetics | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Survival Rate | Lymphatic Metastasis | Brain Neoplasms - drug therapy | Mutation - genetics | Breast Neoplasms - drug therapy | Class I Phosphatidylinositol 3-Kinases | Carcinoma, Lobular - metabolism | Trastuzumab | Bone Neoplasms - mortality | Phosphorylation | Prognosis | Receptor, ErbB-2 - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Liver Neoplasms - mortality | Carcinoma, Ductal, Breast - mortality | Carcinoma, Lobular - mortality | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Brain Neoplasms - secondary | In Situ Hybridization | Lung Neoplasms - secondary | Adult | Female | Bone Neoplasms - drug therapy | Neoplasm Invasiveness | Liver Neoplasms - drug therapy | PTEN Phosphohydrolase - metabolism | Phosphatidylinositol 3-Kinases - genetics | Breast Neoplasms - mortality | Aged | Carcinoma, Lobular - drug therapy | Regular
Journal Article
JAMA surgery, ISSN 2168-6254, 07/2017, Volume 152, Issue 7, pp. 672 - 678
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 03/2013, Volume 8, Issue 3, pp. 346 - 351
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 65, Issue 2, pp. 270 - 273
Journal Article
Blood, ISSN 1528-0020, 2012, Volume 119, Issue 24, pp. 5795 - 5806
The pathogenesis of hepatosplenic T-cell lymphoma (HSTL), a rare entity mostly derived from γδ T cells and usually with a fatal outcome, remains largely... 
GAMMA-DELTA | TYROSINE KINASE | ALPHA-BETA | NON-HODGKINS-LYMPHOMA | NK-CELL | PI EXPRESSION | RECEPTOR | DRUG-RESISTANCE | HEMATOLOGY | NF-KAPPA-B | CLINICOPATHOLOGICAL ENTITY | Crystallins - metabolism | Protein-Tyrosine Kinases - metabolism | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Molecular Sequence Data | Male | Receptors, Antigen, T-Cell, gamma-delta - genetics | Gene Expression Profiling | Intracellular Signaling Peptides and Proteins - metabolism | Molecular Targeted Therapy | Young Adult | Base Sequence | Biomarkers, Tumor - metabolism | Adult | Female | Liver Neoplasms - pathology | Membrane Proteins - metabolism | Genes, Neoplasm - genetics | Syk Kinase | Cell Lineage - genetics | Splenic Neoplasms - drug therapy | Liver Neoplasms - genetics | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Splenic Neoplasms - genetics | Liver Neoplasms - drug therapy | Lymphoma, T-Cell - genetics | Receptors, Antigen, T-Cell, alpha-beta - genetics | Isochromosomes - genetics | Drug Resistance, Neoplasm - genetics | Lymphoma, T-Cell - drug therapy | Splenic Neoplasms - pathology | Chromosome Aberrations | Lymphoma, T-Cell - pathology | Aged | Biomarkers, Tumor - genetics | Cluster Analysis | Protein-Tyrosine Kinases - antagonists & inhibitors | pathology | Lymphoma, T-Cell | Genes, Neoplasm | Drug Resistance, Neoplasm | Isochromosomes | Liver Neoplasms | genetics | Crystallins | Receptors, Antigen, T-Cell, alpha-beta | drug therapy | Tumor Markers, Biological | Intracellular Signaling Peptides and Proteins | antagonists & inhibitors | Membrane Proteins | Cell Lineage | Receptors, Antigen, T-Cell, gamma-delta | metabolism | Protein-Tyrosine Kinases | Splenic Neoplasms
Journal Article
BMC cancer, ISSN 1471-2407, 2006, Volume 6, Issue 1, pp. 225 - 225
Background: HER2/neu overexpression is linked to promotion of angiogenesis in breast cancer. We therefore tested the activity of the combination of Trastuzumab... 
PROTEIN | ANGIOGENESIS | ONCOLOGY | NEU ONCOGENE | EPIDERMAL-GROWTH-FACTOR | IN-VIVO | PHASE-II | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | FACTOR RECEPTOR | PLUS | Lung Neoplasms - drug therapy | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Neoplasm Proteins - immunology | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Cyclophosphamide - adverse effects | Bone Neoplasms - blood supply | Leukopenia - chemically induced | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Liver Neoplasms - secondary | Combined Modality Therapy | Lung Neoplasms - therapy | Lymphatic Metastasis | Breast Neoplasms - blood supply | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Remission Induction | Methotrexate - adverse effects | Breast Neoplasms - genetics | Brain Neoplasms - therapy | Immunization, Passive | Methotrexate - administration & dosage | Trastuzumab | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bone Neoplasms - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Brain Neoplasms - blood supply | Liver Neoplasms - therapy | Ventricular Dysfunction, Left - chemically induced | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Brain Neoplasms - secondary | Lung Neoplasms - secondary | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Bone Neoplasms - drug therapy | Neutropenia - chemically induced | Lung Neoplasms - blood supply | Drug Administration Schedule | Liver Neoplasms - drug therapy | Treatment Outcome | Gene Amplification | Liver Neoplasms - blood supply | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Genes, erbB-2 | Aged
Journal Article
Cell stem cell, ISSN 1934-5909, 2010, Volume 6, Issue 6, pp. 603 - 615
Recent evidence suggests that a subpopulation of cancer cells, cancer stem cells (CSCs), is responsible for tumor growth in colorectal cancer. However,... 
STEMCELL | CELLCYCLE | BREAST-CANCER | INITIATING CELLS | DIPEPTIDYL-PEPTIDASE-IV | CARCINOMA CELLS | EXTRACELLULAR-MATRIX | ACUTE MYELOID-LEUKEMIA | E-CADHERIN | IDENTIFICATION | TUMOR-GROWTH | HUMAN PANCREATIC-CANCER | CELL & TISSUE ENGINEERING | CELL BIOLOGY | Neoplasm Transplantation | RNA, Small Interfering - genetics | Prognosis | Follow-Up Studies | Apoptosis - drug effects | Neoplastic Stem Cells - drug effects | Colorectal Neoplasms - genetics | Humans | Apoptosis - genetics | Gene Expression Profiling | Colorectal Neoplasms - diagnosis | Organoplatinum Compounds - pharmacology | Neoplastic Stem Cells - metabolism | Cell Transformation, Neoplastic - genetics | Colorectal Neoplasms - drug therapy | Liver Neoplasms - physiopathology | Neoplastic Stem Cells - pathology | Tumor Burden - genetics | Tumor Cells, Cultured | Liver Neoplasms - secondary | Colorectal Neoplasms - metabolism | Carcinoma - secondary | Carcinoma - drug therapy | Liver Neoplasms - genetics | Dipeptidyl Peptidase 4 - biosynthesis | Liver Neoplasms - drug therapy | Carcinoma - diagnosis | Dipeptidyl Peptidase 4 - genetics | Mice, SCID | Carcinoma - physiopathology | Disease Progression | Colorectal Neoplasms - physiopathology | Drug Resistance, Neoplasm - genetics | Animals | Liver Neoplasms - diagnosis | Tumor Burden - drug effects | Liver Neoplasms - metabolism | Carcinoma - genetics | Biomarkers, Tumor - genetics | Fluorouracil - pharmacology | Mice | Carcinoma - metabolism | Colorectal Neoplasms - pathology | Neoplasm Invasiveness - genetics | Cell Migration Assays | Biomarkers, Tumor - biosynthesis
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 07/2011, Volume 6, Issue 7, pp. 1236 - 1241
Surgical resection of residual tumor mass in responders to platinum-based chemotherapy has evolved as the preferred treatment of primary mediastinal... 
Mediastinal Mass | Tumor Markers | Surgery | Germ Cell Tumor | SYSTEM | CLASSIFICATION | CANCER | CHEMOTHERAPY | MODERN THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | ADJUNCTIVE SURGERY | EXPERIENCE | Neoplasm, Residual - pathology | Lung Neoplasms - drug therapy | Follow-Up Studies | Neoplasm, Residual - surgery | Humans | Middle Aged | Bone Neoplasms - secondary | Neoplasm Recurrence, Local - drug therapy | Male | Teratoma - surgery | Neoplasm Recurrence, Local - surgery | Brain Neoplasms - surgery | Neoplasm Recurrence, Local - pathology | Young Adult | Brain Neoplasms - secondary | Mediastinal Neoplasms - drug therapy | Lung Neoplasms - secondary | Time Factors | Adult | Female | Neoplasms, Germ Cell and Embryonal - drug therapy | Retrospective Studies | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Mediastinal Neoplasms - surgery | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Survival Rate | Treatment Outcome | Bone Neoplasms - surgery | Brain Neoplasms - drug therapy | Teratoma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Teratoma - drug therapy | Adolescent | Neoplasm, Residual - drug therapy | Lung Neoplasms - surgery | Neoplasms, Germ Cell and Embryonal - surgery | Neoplasm Staging | Neoplasms, Germ Cell and Embryonal - pathology | Testicular Neoplasms
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 6, pp. 976 - 983
...) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer... 
SURVIVAL | COMBINATIONS | MULTICENTER | AMPLIFICATION | THERAPY | EFFICACY | ONCOLOGY | SAFETY | PRETREATED PATIENTS | ANTIBODY | PACLITAXEL | Prognosis | Receptor, ErbB-2 - genetics | Capecitabine | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Bone Neoplasms - secondary | Soft Tissue Neoplasms - drug therapy | Bone Neoplasms - metabolism | Breast Neoplasms - metabolism | Feasibility Studies | Young Adult | Antibodies, Monoclonal, Humanized | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Fluorouracil - analogs & derivatives | Soft Tissue Neoplasms - secondary | Deoxycytidine - administration & dosage | Liver Neoplasms - drug therapy | Soft Tissue Neoplasms - metabolism | In Situ Hybridization, Fluorescence | Survival Rate | Treatment Outcome | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | International Agencies | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Liver Neoplasms - metabolism | Aged | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Trastuzumab | Liver Neoplasms | Breast Neoplasms | Life Sciences | Immunology | Taxoids | Fluorouracil | Antineoplastic Combined Chemotherapy Protocols | Antibodies, Monoclonal | Bone Neoplasms | Receptor, erbB-2 | Deoxycytidine | Soft Tissue Neoplasms
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 2011, Volume 12, Issue 6, pp. 380 - 386
Micro-Abstract We evaluated EGFR and KRAS mutations between 37 paired primary tumors and corresponding metastases in lung adenocarcinoma. A substantial... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Lung adenocarcinoma | Metastasis | Mutation | Epidermal growth factor receptor | Pleura | GENE-MUTATIONS | PRIMARY TUMORS | GEFITINIB | GROWTH-FACTOR-RECEPTOR | KRAS MUTATION | TREATED PATIENTS | CANCER | LYMPH-NODE METASTASIS | ONCOLOGY | BRAIN METASTASES | PROGRESSION | Adrenal Gland Neoplasms - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | ras Proteins - genetics | Pleural Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Bone Neoplasms - secondary | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Pleural Neoplasms - drug therapy | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Polymerase Chain Reaction | Aged, 80 and over | Adrenal Gland Neoplasms - secondary | Adult | Female | Adenocarcinoma - genetics | Bone Neoplasms - genetics | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Lung Neoplasms - genetics | Pleural Neoplasms - secondary | Liver Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Liver Neoplasms - drug therapy | Brain Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Brain Neoplasms - drug therapy | Mutation - genetics | Adenocarcinoma - drug therapy | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | DNA, Neoplasm - genetics | Neoplasm Staging | Adrenal Gland Neoplasms - genetics
Journal Article
Annals of oncology, ISSN 0923-7534, 2018, Volume 29, Issue 8, pp. 1869 - 1876
Journal Article
BMC cancer, ISSN 1471-2407, 2013, Volume 13, Issue 1, pp. 263 - 263